7Baggers

We provide you with 20 years of free, institutional-grade data for ZNTL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ZNTL. Explore the full financial landscape of ZNTL stock.

Reported DateCIKTickerType
2025-08-061725160ZNTL10-QUrl
2025-05-141725160ZNTL10-QUrl
2025-03-261725160ZNTL10-KUrl
2024-11-121725160ZNTL10-QUrl
2024-08-091725160ZNTL10-QUrl
2024-05-071725160ZNTL10-QUrl
2024-02-271725160ZNTL10-KUrl
2023-11-061725160ZNTL10-QUrl
2023-08-091725160ZNTL10-QUrl
2023-05-101725160ZNTL10-QUrl
2023-03-011725160ZNTL10-KUrl
2022-11-091725160ZNTL10-QUrl
2022-08-091725160ZNTL10-QUrl
2022-05-051725160ZNTL10-QUrl
2022-02-241725160ZNTL10-KUrl
2021-11-101725160ZNTL10-QUrl
2021-08-121725160ZNTL10-QUrl
2021-05-171725160ZNTL10-QUrl
2021-03-251725160ZNTL10-KUrl
2020-11-091725160ZNTL10-QUrl
2020-08-131725160ZNTL10-QUrl
2020-07-271725160ZNTLS-1Url
2020-05-151725160ZNTL10-QUrl
2020-03-061725160ZNTLS-1Url

Zentalis Pharmaceuticals, Inc
(NASDAQ:ZNTL) 

ZNTL stock logo

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical ...

Full Time Employees: 110
CEO: Anthony Y. Sun  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about ZNTL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.